Welcome, Guest. Please login or register.
August 18, 2018, 06:41:14 pm

Login with username, password and session length


Members
  • Total Members: 5872
  • Latest: Angel2
Stats
  • Total Posts: 52422
  • Total Topics: 4307
  • Online Today: 60
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 34
Total: 34

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Liver Disease Researchers Struggle to Find Patients for Clinical Trials  (Read 3964 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 500
    • Hep Mag
As the rate of liver disease continues to rise along with the rate of obesity, more than a dozen pharmaceuticals are racing to develop treatments for non-alcoholic steatohepatitis (NASH), a liver condition caused by fat accumulation and characterized by inflammation or damage to the liver. However, according to a recent report in Bloomberg, these drugmakers face a major hurdle: a dearth of patients willing to volunteer for clinical trials to test the new treatments.

The article notes that the treatment market for NASH is currently predicted to reach as much as $40 billion by 2025. Intercept Pharmaceuticals, Genfit and more than a dozen other drug companies are currently locked in a race to develop first-generation drugs to treat the illness. However, executives and physicians overseeing clinical trials of these medications say it’s been difficult to fill patient rosters.

For instance, Intercept managed to fully enroll just one key trial this year, and that was only after it made changes that enabled it to almost halve the number of participants in the study. Earlier this year, a late-stage study at Genfit was delayed by months, prompting the French company to work with medical centers and doctors to persuade more patients to join.

Read more...
https://www.hepmag.com/article/liver-disease-researchers-struggle-find-patients-clinical-trials

 


© 2018 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.